Pharma Capital

Dimerix Ltd to reveal Phase 2 trial results on Chronic Kidney Disease

The halt will remain in place until Thursday 13th July 2017.
Chronic Kidney Disease affects over 10% of the population

Dimerix Ltd (ASX:DXB) is preparing to take investors through the results of its Phase 2 trial results on Chronic Kidney Disease, with the ASX granting the company a trading halt to prepare.

The results will be a key inflection point for the company.

The halt will remain in place until the opening of trade on Thursday 13th July 2017, or earlier if an announcement is made to the market.

Register here to be notified of future DXB Company articles
View full DXB profile

Dimerix Ltd Timeline

View All

Related Articles

If UniBio’s plans come to fruition it won’t be too long before the company orchestrates a major adjustment to the food-chain.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.